Item 8.01. Other Events.

On February 5, 2013, Idera Pharmaceuticals, Inc. (the "Company") received a determination from the NASDAQ Listing Qualifications Panel (the "Panel") indicating that the Panel has granted the Company's request to transfer its listing from The NASDAQ Global Market to The NASDAQ Capital Market, and to continue the Company's listing on that market, provided that the Company has satisfied the $2.5 million stockholders' equity requirement for continued listing on that market on or before March 31, 2013, among other actions, and otherwise meets the continued listing requirements of The NASDAQ Capital Market The Company's securities began trading on The NASDAQ Capital Market effective with the open of business on Thursday, February 7, 2013. The Company's common stock will continue to trade on NASDAQ under the symbol IDRA.

The determination follows the Company's hearing before the Panel, at which the Panel considered the Company's plan to evidence compliance with the stockholders' equity requirement for continued listing on The NASDAQ Capital Market.

- 2 -

---